Myovant Sciences Ltd. (MYOV) Income Statement Analysis

See more : Vivaa Tradecom Limited (VIVAA.BO) Income Statement Analysis – Financial Results

Complete financial analysis of Myovant Sciences Ltd. (MYOV) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Myovant Sciences Ltd., a leading company in the Biotechnology industry within the Healthcare sector.

You may be interested

Myovant Sciences Ltd. (MYOV)

Industry: Biotechnology

Sector: Healthcare

Website: https://myovant.com

About Myovant Sciences Ltd.

Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, which is in Phase II clinical trial for the treatment of female infertility as part of assisted reproduction. Myovant Sciences Ltd. has collaboration with Pfizer Inc. to develop and commercialize relugolix in oncology and women's health. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was incorporated in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. is a subsidiary of Sumitovant Biopharma Ltd.

Metric	2022	2021	2020	2019	2018	2017
Revenue	230.97M	59.32M	0.00	0.00	0.00	0.00
Cost of Revenue	51.55M	1.97M	0.00	0.00	0.00	0.00
Gross Profit	179.42M	57.35M	0.00	0.00	0.00	0.00
Gross Profit Ratio	77.68%	96.69%	0.00%	0.00%	0.00%	0.00%
Research & Development	107.40M	136.71M	192.56M	222.61M	116.83M	43.50M
General & Administrative	0.00	0.00	82.33M	42.22M	24.23M	12.36M
Selling & Marketing	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	259.36M	181.42M	82.33M	42.22M	24.23M	12.36M
Other Expenses	40.04M	1.66M	1.62M	-309.00K	67.00K	-139.00K
Operating Expenses	366.77M	318.14M	274.89M	264.83M	141.06M	55.86M
Cost & Expenses	418.32M	320.10M	274.89M	264.83M	141.06M	55.86M
Interest Income	384.00K	211.00K	2.55M	881.00K	0.00	0.00
Interest Expense	13.97M	10.40M	12.66M	8.82M	2.05M	0.00
Depreciation & Amortization	3.46M	2.69M	1.77M	438.00K	243.00K	61.00K
EBITDA	-183.89M	-258.09M	-273.80M	-255.88M	-140.75M	0.00
EBITDA Ratio	-79.62%	-435.11%	0.00%	0.00%	0.00%	0.00%
Operating Income	-187.35M	-260.78M	-270.71M	-264.83M	-141.06M	-55.86M
Operating Income Ratio	-81.11%	-439.64%	0.00%	0.00%	0.00%	0.00%
Total Other Income/Expenses	-13.59M	5.99M	-17.51M	-8.25M	-1.98M	-27.66M
Income Before Tax	-200.93M	-254.80M	-288.23M	-273.08M	-143.04M	-83.51M
Income Before Tax Ratio	-86.99%	-429.55%	0.00%	0.00%	0.00%	0.00%
Income Tax Expense	5.05M	336.00K	761.00K	476.00K	213.00K	-74.00K
Net Income	-205.98M	-255.13M	-288.99M	-273.55M	-143.26M	-83.44M
Net Income Ratio	-89.18%	-430.12%	0.00%	0.00%	0.00%	0.00%
EPS	-2.22	-2.83	-3.37	-4.09	-2.41	-1.70
EPS Diluted	-2.22	-2.83	-3.37	-4.09	-2.41	-1.70
Weighted Avg Shares Out	92.97M	90.04M	85.84M	66.91M	59.52M	49.18M
Weighted Avg Shares Out (Dil)	92.97M	90.04M	85.84M	66.91M	59.52M	49.18M

Myovant and Partner Get Key Drug Approval

June 16, 2021gurufocus.com

A lesser-known British biotech is among eight pharma companies the publication Kiplinger encouraged readers to monitor for important key clinical trial results or regulatory approvals.

Myovant Sciences: Becoming A Blockbuster

June 2, 2021seekingalpha.com

Myovant recently cleared another regulatory binary for relugolix as a treatment for uterine fibroids. On top of the clearance for advanced prostate cancer, Relugolix is now approved for two indications.

Myovant Sciences to Present at Upcoming Investor Conferences

June 1, 2021globenewswire.com

BASEL, Switzerland, June 01, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, invites investors and the general public to listen to webcasts at the following investor conferences:

Myovant - Pfizer's Uterine Fibroids Treatment Wins FDA Approval

May 27, 2021benzinga.com

The FDA has approved Myovant Sciences Ltd (NYSE: MYOV) and Pfizer Inc's (NYSE: PFE) relugolix combined with estradiol and norethindrone acetate for heavy menstrual bleeding linked to uterine fibroids in premenopausal women. The once-daily treatment will be marketed as Myfembree, with a treatment duration of...

Sumitovant Biopharma Has a Strong Fourth Quarter with Significant Clinical Development and Corporate Achievements Across its Portfolio of Companies

May 26, 2021prnewswire.com

LONDON and NEW YORK, May 26, 2021 /PRNewswire/ -- Sumitovant Biopharma, Inc. today announced that its portfolio of four wholly owned subsidiary companies (Urovant, Enzyvant, Altavant and Spirovant) and Myovant Sciences (NYSE: MYOV), a publicly listed company that is majority owned by Sumitovant, achieved significant...

Myovant Sciences' Relugolix Combo Tablet For Uterine Fibroids Scores EMA Backing For Approval

May 21, 2021benzinga.com

European Medicines Agency's advisory committee issued a positive opinion recommending the approval of Myovant Sciences Ltd's (NYSE: MYOV) Ryeqo (relugolix, estradiol, and norethindrone acetate) for uterine fibroids. The final decision on the application is expected to be available in approximately two months.

Myovant Sciences Receives Positive CHMP Opinion for RYEQO® (Relugolix Combination Tablet) for the Treatment of Women With Uterine Fibroids

May 21, 2021globenewswire.com

BASEL, Switzerland, May 21, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion recommending the approval of RYEQO® (relugolix 40 mg,...